Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Bonora

Showing results (201-210 of 302) with videos related to

Pageof 31
Sort By:
World Journal of Clinical Cases|April 22, 2014
Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIVStefano Salizzoni, Fabrizio D'Ascenzo, Claudio Moretti, et al.
Viruses|March 6, 2021
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic PatientsMattia Trunfio, Francesco Venuti, Francesca Alladio, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|October 31, 2023
Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment RegimenGiacomo Stroffolini, Alessandro Lazzaro, Ambra Barco, et al.
Thrombosis and Haemostasis|May 25, 2013
In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patientsEmanuela Falcinelli, Daniela Francisci, Barbara Belfiori, et al.
Plos One|October 8, 2016
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeSilvia Costarelli, Alessandro Cozzi-Lepri, Giuseppe Lapadula, et al.
Metabolites|December 23, 2022
Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic StudyJessica Cusato, Alberto Borghetti, Elisabetta Teti, et al.
The Journal of Antimicrobial Chemotherapy|January 20, 2009
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosisFrancesca Gatti, Paola Nasta, Arianna Loregian, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 22, 2020
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohortsRoberto Rossotti, Alessandro Tavelli, Stefano Bonora, et al.
The Journal of Antimicrobial Chemotherapy|December 11, 2012
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cellsAntonio D'Avolio, Marco Simiele, Andrea Calcagno, et al.
Emerging Infectious Diseases|October 6, 2020
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, ItalyAndrea Calcagno, Valeria Ghisetti, Teresa Emanuele, et al.
Pageof 31

Showing results (201-210 of 302) with videos related to

Sort By:
Pageof 31
World Journal of Clinical Cases|April 22, 2014
Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIVStefano Salizzoni, Fabrizio D'Ascenzo, Claudio Moretti, et al.
Viruses|March 6, 2021
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic PatientsMattia Trunfio, Francesco Venuti, Francesca Alladio, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|October 31, 2023
Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment RegimenGiacomo Stroffolini, Alessandro Lazzaro, Ambra Barco, et al.
Thrombosis and Haemostasis|May 25, 2013
In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patientsEmanuela Falcinelli, Daniela Francisci, Barbara Belfiori, et al.
Plos One|October 8, 2016
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeSilvia Costarelli, Alessandro Cozzi-Lepri, Giuseppe Lapadula, et al.
Metabolites|December 23, 2022
Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic StudyJessica Cusato, Alberto Borghetti, Elisabetta Teti, et al.
The Journal of Antimicrobial Chemotherapy|January 20, 2009
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosisFrancesca Gatti, Paola Nasta, Arianna Loregian, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 22, 2020
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohortsRoberto Rossotti, Alessandro Tavelli, Stefano Bonora, et al.
The Journal of Antimicrobial Chemotherapy|December 11, 2012
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cellsAntonio D'Avolio, Marco Simiele, Andrea Calcagno, et al.
Emerging Infectious Diseases|October 6, 2020
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, ItalyAndrea Calcagno, Valeria Ghisetti, Teresa Emanuele, et al.
Pageof 31